As the strength or potency of cannabis products has increased internationally over the years, so have rates of people being treated for cannabis addiction, say the authors of a new study.
Researchers from the Addiction and Mental Health Group at the University of Bath (UK) systematically analyzed the relationship between the types of cannabis people use and their addiction and mental health problems. Their work draws on 20 studies involving almost 120,000 people.
After alcohol and nicotine, diflucan during 2nd trimester cannabis is the most widely used drug globally. Latest estimates from the UK suggest that over the last year around one in five 16-24-year-olds had used cannabis.
Cannabis potency refers to the concentration of tetrahydrocannabinol (THC) in cannabis – the key psychoactive drug it contains. Recent studies from the same team at Bath have found that the concentration of THC in cannabis has increased significantly over time meaning that cannabis used today is typically much stronger than previously.
The new study, published in The Lancet Psychiatry, suggests that people who use high potency cannabis are more likely to experience addiction than those using low potency products. It also suggests that people using high potency cannabis are more likely to experience a psychotic disorder, such as schizophrenia.
These findings may help to explain why more people have received treatment for cannabis problems over recent years. Data from the European Monitoring Centre for Drugs and Drug Addiction show a 76% increase in people entering treatment for cannabis addiction in the past decade.
Based on these new results, the authors argue that public health guidelines and policies to help make cannabis use safer should be encouraged.
Our systematic review found that people who use higher potency cannabis could be at increased risks of addiction as well as psychosis when compared to people who use cannabis products with lower potencies.
These results are important in the context of harm reduction which aims to minimise the negative consequences associated with drug use. While the safest level of use for cannabis is of course 'no use', it is important to acknowledge that a significant number of people across the world use cannabis regularly and to ensure they can make informed decisions that could reduce any possible harms associated with it."
Kat Petrilli, Lead Author, University of Bath's Department of Psychology
The authors point out that strategies to make cannabis use safer could inform how the drug is regulated in the UK and internationally. Recreational cannabis use remains illegal in the UK, but cannabis products are now legally sold for recreational use in Canada, Uruguay, and parts of the USA.
Several other countries appear set to follow this trend, including Germany. In the UK, the Liberal Democrats have argued that a legal regulated market could make cannabis use safer by enforcing a limit on the potency of cannabis products, and investing the revenue and savings from this into education and treatment for cannabis problems.
Senior author, Dr Tom Freeman explained: "Our findings suggest that people who use cannabis could reduce their risk of harm by using lower potency products. In places where cannabis is legally sold, providing consumers with accurate information on product content and access to lower potency products could help people to use cannabis more safely."
Despite anecdotal evidence of links between cannabis and anxiety and depression, the authors note that the links between cannabis potency and other mental health problems are unclear.
This research was funded by the Economic and Social Research Council.
University of Bath
Petrilli, K., et al. (2022) Association of cannabis potency with mental ill health and addiction: a systematic review. The Lancet Psychiatry. doi.org/10.1016/S2215-0366(22)00161-4.
Posted in: Medical Research News | Medical Condition News | Healthcare News
Tags: Addiction, Alcohol, Anxiety, Cannabis, Depression, Drugs, Education, Mental Health, Nicotine, Psychiatry, Psychology, Psychosis, Public Health, Research, Schizophrenia, Tetrahydrocannabinol
Source: Read Full Article